Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link?

Flavia Mesquita Gava, Bonnie Yates, Grace Li, Chelsea O'Koren, Biplov Adhikari, Haneen Shalabi, Evrim Turkbey, Constance Yuan, Hao-Wei Wang, Sara Silbert, Nirali Shah

Blood (2025) 146 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2025-5099

Published: 2025

Journal Articles

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Chelsea O'Koren, Julie Ma, Bonnie Yates, Hao-Wei Wang, Constance Yuan, Chloe Hoang, Tanvi Verma, David Peske, Ilan Kirsch, Challice Bonifant, Nirali Shah

Blood (2025) 146 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2025-3363

Published: 2025

Journal Articles

Single-cell metabolic profiling of post-infusion CD22 and CD19/CD22 CAR T-cells reveals a shift toward amino acid–driven oxphos informing SLC-armored CAR design

Blood (2025) 146 (Supplement 1): 502.

https://doi.org/10.1182/blood-2025-502

Published: 2025

Journal Articles

A novel immune signature characterized by activation of the IFNγ-IL18 axis identifies immune effector cell-associated HLH-like syndrome after CD22 chimeric antigen receptor T-cell therapy

Joseph Rocco, Brett Schroeder, Logan Cook, Bonnie Yates, Brian Sellers, Thomas Langowski, Colton McNinch, Irina Maric, Michelly Sampaio De Melo, Irini Sereti, Nirali Shah

Blood (2025) 146 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2025-2344

Published: 2025

Journal Articles

CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results

Sara Silbert, Flavia Gava, Bonnie Yates, Alexander Rankin, Lauren Little, Toni Foley, Alexandra Dreyzin, Christopher Chien, Naomi Taylor, Terry Fry, Constance Yuan, Hao-Wei Wang, David Stroncek, Steven Highfill, Haneen Shalabi, Nirali Shah

Blood (2025) 146 (Supplement 1): 814.

https://doi.org/10.1182/blood-2025-814

Published: 2025

Journal Articles

Utility of peripheral blood cell-free DNA in detecting minimal residual disease in patients receiving CAR T-cell therapy for B-acute lymphoblastic leukemia (B-ALL)

Yannan Wang, Xiaolin Wu, Brynn Duncan, Chloe Hoang, Bonnie Yates, Chloe Sachs, Victoria Giordani, Nirali Shah, Russell Sundby

Blood (2025) 146 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2025-1591

Published: 2025

Journal Articles

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Marc Schwartz, Navin Pinto, Michael Verneris, Daniel Pollyea, Christine McMahon, Jonathan Gutman, Angela Ohm, Maria Amaya, Andrew Kent, Mathew Angelos, Cheri Adams, Bonnie Yates, Katie Anttila, Jessica Dell-Martin, Kimberly Jordan, Terry Fry

Blood (2025) 146 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2025-4165

Published: 2025

Journal Articles

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S. Nair, Sara K. Silbert, Kai Rejeski, Karilynn A. Wilson, Adam J. Lamble, Yannis Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin Curran, Rebecca A. Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N. Shah

Blood (2025) 145 (11): 1136–1148.

https://doi.org/10.1182/blood.2024025910

Published: 2025

Includes: Supplemental data

Journal Articles

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Jacinta Davis, JuanCarlos Balandrán, Katharina Hayer, Sisi Zheng, Zhiwei Ang, Evelyn Liu, Bonnie Yates, Nirali N. Shah, Iannis Aifantis, Andrei Thomas-Tikhonenko

Blood (2024) 144 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2024-208185

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Joseph M. Rocco, Elizabeth Laidlaw, Bonnie Yates, Brett Schroeder, Emily Limerick, William T. Johnson, Joseph H. Oved, Frances Galindo, Whitney Ewing, Courtney Fitzhugh, Maura Manion, Andrea Lisco, Steven Holland, Nirali N. Shah, Irini Sereti

Blood (2024) 144 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2024-210363

Published: 2024

Journal Articles

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Alexandra Dreyzin, Yihua Cai, Kyu Lee Han, Michaela Prochazkova, Jennifer Webb, Keri Toner, Kathryn Bushnell, Bonnie Yates, Ping Jin, David F. Stroncek, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2024-199264

Published: 2024

Journal Articles

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Tommaso Balestra, Camilo Arenas Merizalde, Robert K Chen, John Roach, Brian Bowser, Rachelle Salomon, Anthony Welch, Bonnie Yates, Kristin Schaller, Michael R Verneris, Susanne H.C. Baumeister, Emily M. Hsieh, M. Eric Kohler, Katherine Tarlock, Steven M. Devine, Richard Aplenc, Nirali N. Shah, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 369.

https://doi.org/10.1182/blood-2024-211517

Published: 2024

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Blood (2021) 138 (24): 2469–2484.

https://doi.org/10.1182/blood.2021011898

Published: 2021

Includes: Supplemental data

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Sara K. Silbert, Elizabeth M. Holland, Seth M. Steinberg, Lauren Little, Toni Foley, Haneen Shalabi, Bonnie Yates, Nirali N. Shah

Blood (2021) 138 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2021-146979

Published: 2021

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link?

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Single-cell metabolic profiling of post-infusion CD22 and CD19/CD22 CAR T-cells reveals a shift toward amino acid–driven oxphos informing SLC-armored CAR design

A novel immune signature characterized by activation of the IFNγ-IL18 axis identifies immune effector cell-associated HLH-like syndrome after CD22 chimeric antigen receptor T-cell therapy

CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results

Utility of peripheral blood cell-free DNA in detecting minimal residual disease in patients receiving CAR T-cell therapy for B-acute lymphoblastic leukemia (B-ALL)

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only